Moderna Inc. [NASDAQ: MRNA] closed the trading session at $138.30 on 12/21/20. The day’s price range saw the stock hit a low of $137.79, while the highest price level was $147.26. The company report on December 20, 2020 that U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older.
Recommendation follows yesterday’s U.S. FDA authorization for emergency use of the Moderna COVID-19 Vaccine.
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). The committee is comprised of independent health experts. 11 ACIP members voted in favor of the vaccine and 0 members voted against.
The stocks have a year to date performance of 607.06 percent and weekly performance of -10.81 percent. The stock has been moved at 119.73 percent over the last six months. The stock has performed 49.08 percent around the most recent 30 days and changed 101.25 percent over the most recent 3-months.
If compared to the average trading volume of 18.39M shares, MRNA reached to a volume of 23658373 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Moderna Inc. [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $129.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on December 16, 2020. While these analysts kept the previous recommendation, Jefferies dropped their target price from $90 to $150. The new note on the price target was released on December 16, 2020, representing the official price target for Moderna Inc. stock.
The Average True Range (ATR) for Moderna Inc. is set at 12.37, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 227.80. The Price to Book ratio for the last quarter was 19.79, with the Price to Cash per share for the same quarter was set at 8.06. Price to Free Cash Flow for MRNA in the course of the last twelve months was 91.69 with Quick ratio for the last quarter at 2.40.
MRNA stock trade performance evaluation
Moderna Inc. [MRNA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.81. With this latest performance, MRNA shares gained by 49.08% in over the last four-week period, additionally plugging by 119.73% over the last 6 months – not to mention a rise of 597.43% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 54.98, with the RSI for the last a single of trading hit 48.48, and the three-weeks RSI is set at 58.17 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 103.07, while it was recorded at 141.36 for the last single week of trading, and 69.98 for the last 200 days.
Moderna Inc. [MRNA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -906.38. Moderna Inc.’s Net Margin is presently recorded at -853.73.
Return on Total Capital for MRNA is now -37.83, given the latest momentum, and Return on Invested Capital for the company is -35.81. Return on Equity for this stock declined to -38.00, with Return on Assets sitting at -28.95. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 11.57. Additionally, MRNA Total Debt to Total Capital is recorded at 10.37, with Total Debt to Total Assets ending up at 8.55. Long-Term Debt to Equity for the company is recorded at 11.27, with the Long-Term Debt to Total Capital now at 10.10.
Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of -$619,302 per employee. Receivables Turnover for the company is 2.57 with a Total Asset Turnover recorded at a value of 0.03.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.40.
Earnings per share (EPS) analysis for Moderna Inc. [MRNA] stock
With the latest financial reports released by the company, Moderna Inc. posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
Moderna Inc. [MRNA]: Insider Ownership positions
There are presently around $28,112 million, or 52.00% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: FMR LLC with ownership of 34,221,324, which is approximately -8.821% of the company’s market cap and around 2.10% of the total institutional ownership; FLAGSHIP PIONEERING INC., holding 30,871,524 shares of the stock with an approximate value of $4.27 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $3.86 billion in MRNA stock with ownership of nearly 8.779% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 352 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 14,852,860 shares. Additionally, 212 investors decreased positions by around 29,537,861 shares, while 48 investors held positions by with 158,875,643 shares. The mentioned changes placed institutional holdings at 203,266,364 shares, according to the latest SEC report filing. MRNA stock had 139 new institutional investments in for a total of 1,793,633 shares, while 77 institutional investors sold positions of 3,768,807 shares during the same period.